Skip to content
Search

Latest Stories

Sebastian James to step down as Boots Managing Director

Sebastian James to step down as Boots Managing Director

Boots have already started the process of recruiting a new Managing Director

Walgreens Boots Alliance (WBA) has officially announced that Sebastian James, the Managing Director of Boots, will be stepping down from his role to pursue a new opportunity in the healthcare sector.


James has given notice to leave the company and will remain with Boots until November. The UK pharmacy giant has already begun the search for a new Managing Director.

James is set to take on the role of CEO at Veonet, a leading European chain of ophthalmology clinics.

During his tenure as Managing Director since 2018, James played a pivotal role in transforming Boots into the UK’s leading health and beauty retailer.

He oversaw significant growth and innovation, achieving thirteen consecutive quarters of retail market share growth. Most recently, the company announced strong Q3 results in June with growth across all categories.

Sebastian contributed to reinventing Boots' beauty business by introducing hundreds of new brands, refurbishing beauty halls across the UK, and hiring more specialist beauty advisors.

Under his leadership, Boots expanded its healthcare services significantly, now offering over 160 healthcare services to both private and NHS patients.

Ornella Barra, Chief Operating Officer, International at Walgreens Boots Alliance, thanked James for his contributions to the company's success over the years, stating, "His tenure has seen the company transform through a steadfast focus on investment, innovation, and growth into the No.1 health and beauty destination in the UK.

“We thank Sebastian for his commitment, along with the Boots leadership team, to delivering a strong platform for sustainable, long-term growth, and we wish him all the best for his next endeavor."

Commenting on his departure, James remarked: "It has been a pleasure to lead this fantastic company and support its transformation during my time as Managing Director.

“Now in its 175th year, Boots has shaped how people access health and beauty products on the high street, and I am proud to have been part of a business that continues to play a critical role in the UK health and beauty sectors.

“I look forward to seeing the business continue to succeed under its excellent leadership team."

His exit comes as Boots’ parent company, WBA, suspended its plans for a sale or stock market listing of the pharmacy chain.

More For You

GPhC should consider reduced fees for pharmacists non-practising practising, says RPS

RPS responds to GPhC consultation on draft changes to fees

gettyimages

RPS urges GPhC to reduce registration fees for non-practising pharmacists

The Royal Pharmaceutical Society (RPS) has called on the General Pharmaceutical Council (GPhC) to reduce annual registration fees for non-practising pharmacists — such as those on parental leave or with a long-term illness — in response to the regulator’s consultation on proposed changes to fees.

The GPhC is proposing a 6% increase in annual registration fees from September 2025 to cover the rising operational costs.

Keep ReadingShow less
Hay fever treatment: Dymista nasal spray now available in pharmacies without prescription

Hay fever affects one in four people in the UK

gettyimages

Hay fever treatment: First OTC combination nasal spray launched

For the first time, a double-action combination treatment for moderate to severe hay fever has been available over the counter across UK pharmacies, offering a new option for those sufferers who remain uncontrolled on a corticosteroid or antihistamine nasal spray.

Launched by global healthcare company Viatris, Dymista® CONTROL (azelastine hydrochloride and fluticasone propionate) nasal spray— previously only available via prescription under the brand name Dymista — can be accessed without a GP visit.

Keep ReadingShow less
Nick Kaye
Nick Kaye appointed as NPA's new chair
Nick Kaye appointed as NPA's new chair

Breaking news: NPA members advised against collective action

With the government’s recent announcement of increased funding to the sector signalling a ‘clear step forward’, the National Pharmacy Association (NPA) has today announced that it will not be recommending collective action to its members.

Last month, the department of health announced the Community Pharmacy Contractual Framework (CPCF) with an increase in funding for 2024/25 of £106m to £2.7 billion and simultaneously a further increase to £3.1 billion for 25/26.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less